Publications by authors named "Oday Hamid"

Claim this Profile
E
Enhancing immuno-oncology efficacy with H1-antihistamine in cancer therapy: a review of current research and findings.
Oday Hamid, Negar Hamidi

Curr Med Res Opin· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Tina Cascone, Gozde Kar, Jonathan D Spicer, Rosario García-Campelo, Walter Weder, Oday Hamid

Cancer Discov· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Vincent Ribrag, Seung Tae Lee, David Rizzieri, Martin J S Dyer, Luis Fayad, Oday Hamid

Clin Lymphoma Myeloma Leuk· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
Lillian Siu, Joshua Brody, Shilpa Gupta, Aurélien Marabelle, Antonio Jimeno, Oday Hamid

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, Cora N Sternberg, Oday Hamid

Lancet Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, Cora N Sternberg, Oday Hamid

Lancet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.
Michael Michael, Yung-Jue Bang, Young Suk Park, Yoon-Koo Kang, Tae Min Kim, Oday Hamid

Target Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer.
Ravi Salgia, John R Stille, R Waide Weaver, Michael McCleod, Oday Hamid

Lung Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma.
John D Hainsworth, Edward R Arrowsmith, Michael McCleod, Eric D Hsi, Oday Hamid

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
John D Hainsworth, James A Reeves, Joseph R Mace, Edward J Crane, Oday Hamid

Target Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
Lee Schwartzberg, Robert Hermann, Ian Flinn, Douglas Flora, Eric D Hsi, Oday Hamid

Br J Haematol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas.
Cecily J Forsyth, David Gomez-Almaguer, Johnny F C Camargo, Paul E Eliadis, Erick Crespo-Solis, Oday Hamid

Clin Lymphoma Myeloma Leuk· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma.
Manuela Schmidinger, Cezary Szczylik, Cora N Sternberg, Marek Kania, Claudia Sue Kelly, Oday Hamid

Am J Clin Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.
Christiane Querfeld, Timothy M Kuzel, Youn H Kim, Pierluigi Porcu, Madeleine Duvic, Oday Hamid

Leuk Lymphoma· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.
Susana Campos, Oday Hamid, Michael V Seiden, Amit Oza, Marie Plante

J Clin Oncol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
John Rinehart, Alex A Adjei, Patricia M Lorusso, David Waterhouse, J Randolph Hecht, Oday Hamid

J Clin Oncol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
Oday Hamid

J Am Pharm Assoc (2003)· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.
Oday Hamid, Mary L Varterasian, Scott Wadler, J Randolph Hecht, Al Benson

J Clin Oncol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis